Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01714570|
Recruitment Status : Completed
First Posted : October 26, 2012
Last Update Posted : April 17, 2014
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell transplantation is very limited.
The current study will evaluate the efficacy of piperacillin/tazobactam compared with imipenem/cilastatin for febrile neutropenia after transplantation.
|Condition or disease||Intervention/treatment||Phase|
|Febrile Neutropenia Hematopoietic Stem Cell Transplantation||Drug: Piperacillin-tazobactam combination product Drug: Imipenem||Not Applicable|
- Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room after transplantation.
- Randomize the febrile patients into 2 groups.
- Therapy group receive piperacillin/tazobactam, 4.5g q6h iv. Control group receive imipenem/cilastatin, 0.5g q6h. Duration will be 5-10 days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||123 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||April 2014|
U.S. FDA Resources
Drug: Piperacillin-tazobactam combination product
4.5g q6h, 5-10 days
Other Name: Tazocin
|Active Comparator: imipenem/cilastatin||
0.5g q6h, 5-10 days
Other Name: Tienam
- Clinical success rate. [ Time Frame: 3 weeks after beginning of empirical therapy ]Resolve of clinical symptoms and signs, without change of therapy.
- Microbiologic success rate [ Time Frame: 3 weeks after beginning of empirical therapy ]
Microbiologic success includes eradication, suspected eradication, and super-infection.
- Eradication or Presumed eradication: the baseline pathogens no longer present on the culture performed after completion of treatment. If no way to collect biologic sample(s) after treatment;, e.g. sputum, a presumed eradication will be concluded
- No eradication: one or more baseline pathogens were persistent
- Relapse: the baseline pathogens transient absence reappeared during the therapy
- Alternative: the baseline pathogens were eradicated, but new ones appeared without any clinical signs and symptoms
- Re-infection: the baseline pathogens were eradicated, but new ones appeared with clinical signs and symptoms.
- Adverse effect [ Time Frame: 3 weeks after beginning of empirical therapy ]The number of patients developed unexpected medical information at the 3 weeks after beginning of empirical therapy.
- Cost of drug and therapy [ Time Frame: 3 weeks after beginning of empirical therapy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01714570
|Chinese PLA general hospital|
|Beijing, Beijing, China, 100853|
|Principal Investigator:||wenrong huang, Doctor||Employee|